Phenotypic characteristics of AML donors used in our experiments and outcome of engraftment studies following AAV2/8-mediated hIFN-β expression in vivo
| Patient no. . | Patient characteristics . | Proportion of mice engrafted with AML . | |||
|---|---|---|---|---|---|
| AML . | Flt3/ITD . | WBC count, × 109/L . | hFIX transduced . | hIFN-β transduced . | |
| 1 | M4 | Flt3/ITD+ | 308 | 3/3 | 0/4 |
| 2 | M1 | Flt3/ITD+ | 150 | 5/5 | 0/4 |
| 3 | M1 | Flt3/ITD+ | — | 3/4* | 0/4 |
| Patient no. . | Patient characteristics . | Proportion of mice engrafted with AML . | |||
|---|---|---|---|---|---|
| AML . | Flt3/ITD . | WBC count, × 109/L . | hFIX transduced . | hIFN-β transduced . | |
| 1 | M4 | Flt3/ITD+ | 308 | 3/3 | 0/4 |
| 2 | M1 | Flt3/ITD+ | 150 | 5/5 | 0/4 |
| 3 | M1 | Flt3/ITD+ | — | 3/4* | 0/4 |
Primary AML engraftment was defined as more than 1% tumor infiltration of bone marrow by CD45 FACS analysis.
WBC indicates white blood cells; —, not available.
One death from radiation toxicity.